Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...

The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com. Sign up for ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market. The company announced it would begin a study to see if ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical device company with a market capitalization of $17.7 million focused on addressing obesity, announced today its plan to conduct a ...